

# Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia

NCT07422779

---

Status	RECRUITING
Phase	Not Applicable
Sponsor	Institute of Oncology Ljubljana
Enrollment	100 participants

## Plain Language Summary

---

This study analyzes whether a protein called PD-L1 (found on tumor cells) can predict how well immunotherapy drugs — such as pembrolizumab, nivolumab, or ipilimumab/nivolumab — work in patients with metastatic melanoma (skin cancer that has spread to other parts of the body) in Slovenia.

**\*\*You may be eligible if...\*\***

- You are 18 or older
- You have confirmed metastatic malignant melanoma (stage IIID unresectable or stage IV)
- You are in reasonably good health (ECOG 0–2)
- You are receiving first-line immunotherapy
- You had imaging performed within 4 weeks before starting treatment

**\*\*You may NOT be eligible if...\*\***

- You have already received prior immunotherapy
- You are in poor health
- Your melanoma has not spread

Talk to your doctor to see if this trial is right for you.

## Key Eligibility Criteria

---

### Inclusion (7)

- Age e18 years
- Cytologically or histologically confirmed metastatic malignant melanoma
- Stage IIID unresectable or stage IV (AJCC 8th edition)
- ECOG performance status 0-2
- First-line systemic immunotherapy (pembrolizumab, nivolumab, or ipilimumab/nivolumab)
- ... and 2 more (see full listing online)

### Exclusion (4)

- Previous systemic therapy for melanoma
- ECOG performance status 3-4
- Contraindications to immunotherapy (immune deficiency, active immunosuppressive therapy, or active autoimmune disease requiring systemic treatment)
- Other active malignancy (except cured basal cell carcinoma, squamous cell carcinoma, or other solid tumors without recurrence >3 years)

## Locations (1 total)

---

<https://www.institut-onkologija.si/> Institute of Oncology Ljubljana, Slovenia

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://www.clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://www.clinicaltrialsfinder.org).